The Prognostic Value of Serum Biomarkers in Osteosarcoma

Completed

• Conditions: Osteosarcoma

• Registration Number: NCT05093101
• Lead Sponsor: Istituto Ortopedico Rizzoli

Brief Summary

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-12
• Status Verified: 2021-10
• Study First Submitted: 2021-10-12
• Study First Submitted QC: 2021-10-25
• Study First Posted: 2021-10-26
• Primary Completion: 2021-12-22
• Study Completion: 2021-12-22
• Last Update Submitted: 2022-03-25
• Last Update Posted: 2022-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Osteosarcoma diagnosed at the Pathological Anatomy of the Rizzoli Orthopaedic Institute in Bologna;
• Minimum 2-year follow-up period;
• Medical records, complete blood work and instrumental examinations, regular follow-up;
• Patients with age ≥ 2 years;

Exclusion Criteria

• Patients with osteosarcoma who have received medical treatment (surgery, radiotherapy or chemotherapy) in other hospitals prior to admission to our Institute

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of 5-year survival	5 years	Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental prognostic factors

Secondary Outcome Measures

Name	Time	Method
Evaluation of the rate of local recurrence	5 years	Evaluation of the rate of local recurrence and distant metastasis in relation to histological, laboratory, clinical, and instrumental prognostic factors.

Trial Locations

Locations (1)

IRCCS Itituto Ortopedico Rizzoli; 🇮🇹 Bologna, BO, Italy